2.27M Pfizer COVID-19 vaccines arrived in Philippines on June 10, 2021

Manila, Philippines – The 2.27 million doses of Pfizer-BioNTech COVID-19 vaccines procured by the Philippine government arrived in the country on Thursday evening, June 10, 2021 at Ninoy Aquino International Airport (NAIA) Terminal 3 via DHL Flight LD457.

These vaccines were developed by American corporation called Pfizer in New York (NY) and BioNtech, a German biotechnology company in Mainz, Germany.

According to DOH, the Pfizer-BioNTech doses from COVAX facility will mainly be allocated for Metro Manila, Davao and Cebu areas.

The fist shipment of the Pfizer Covid-19 vaccines to the Philippines was on May 10 with 193,050 doses of Pfizer vaccines.

In a twitter post of Robert Borje, the chief presidential protocol said that the 1.9M doses of Pfizer from COVAX facility arrived in Manila and the 110,000 doses of Pfizer from COVAX facility were delivered in Davao City and 210,000 doses were delivered to Cebu City.

Sec. Roque added that the Pfizer doses from COVAX facility will mainly be allocated to a low temperature areas like Metro Manila, Davao and Cebu because the vaccines requires negative 20 degrees temperature.

According to Pfizer, the vaccine needs to be stored in a ultra-low temperature freezers between -80ºC to -60ºCfor five days at refrigerated 2-8°C conditions.

Chief implementer Carlito Galvez Jr. earlier said the government expects 1.5 million doses of Sinovac Covid-19 vaccines to be delivered on June 17.

In a survey conducted by the Social Weather Station (SWS), the most preferred vaccines of Filipinos are those from Sinovac and Pfizer-BioNTech.

Earlier on Thursday morning, the government has received one (1) Million Sinovac COVID-19 vaccines of Chinese drug-maker Sinovac Biotech.

So far, this is the largest shipment of Covid-19 vaccines that the Philippines has received in a single day with a total of 3.2 million vaccines.

Covid-19 Vaccines Update

The Philippine government has received a total of 12,608,210 Covid-19 doses of vaccines as of June 10, 2021. Majority of the vaccines received by the government are SinoVac Vaccines with a total of 7.5M doses. These vaccines were developed by the Chinese drug-maker Sinovac BioNtech.

Here is the table showing the number of vaccines delivered in the country from February 2021 to present.

DateName of VaccinesFigure
Feb 28, 2021SinoVac600,000
March 24, 2021SinoVac400,000
March 29, 2021SinoVac1,000,000
April 11, 2021SinoVac500,000
April 19, 2021AstraZeneca525,600
April 22, 2021SinoVac500,000
April 29, 2021SinoVac500,000
May 1, 2021Gamaleya30,000
May 7, 2021SinoVac1,500,000
May 8, 2021AstraZeneca2,000,000
May 10, 2021Pfizer-BioNTech193,050
May 19, 2021SinoVac500,000
May 30, 2021Sputnik V50,000
June 6, 2021Sinovac1,000,000
June 10, 2021Sinovac1,000,000
June 10, 2021Pfizer-BioNTech2,279,160

Since the vaccination rolled out by March 1, 2021, 1,681,722 were fully vaccinated and 4,632,826 received their first dose of vaccine. As of June 8, 2021, the Philippine government has administered a total of 6,314,548 doses of vaccines.

Meanwhile, the Philippine government has distributed 8,684,060 doses of COVID vaccines as of June 07, 2021. Each person need 2 doses of COVID-19 vaccine.

The government is also expecting to receive AstraZeneca vaccines from World Health Organization (WHO) and from Pfizer-BioNTech within this year.

The target numbers of full vaccination by the end of the year are at least 58 million individuals.

DOH: Vaccination Priorities

The government approved the vaccination for economic frontline workers in essential sectors (A4) and indigent Filipinos (A5) beginning of June. So far, only health workers, senior citizens and persons with comorbidities have undergone the vaccination program. Here are the following categories in vaccination program.

The Department of Health (DOH) and the World Health Organization (WHO) also emphasized the importance and prioritization of the vaccination program of the government.

“We will use these vaccines among our A1 to A3 priority groups. If we don’t vaccinate them, we will encounter the same packed emergency rooms, unavailable intensive care units, and even hospital beds during the next surge,” DOH Secretary Francisco Duque III said.

“Given the surge in cases in some regions, it is urgent to achieve high vaccination coverage in these A1 to A3 groups to protect those at risk of severe disease and death. WHO urges the National Task Force and the local government units to establish mechanisms to increase accessibility to vaccination of the healthcare workers and elderly across the country,” WHO Country Representative Rabindra Abeyasinghe said.

CategoryPriority group
A1Frontline health workers both national and local; public and non-public; health professional and non-professional (students, nursing aides, janitors, barangay health workers, et. al)
A2Senior citizens (60-years old and above)
A3Persons with comorbidities
A4Economic frontline workers in essential sectors including uniformed personnel.
A5Indigent Filipinos
B1Teachers and Social workers
B2Other Government Workers
B3Other Essential Workers such as grocery store workers, bank workers, retail workers, mall workers
B4Socio-demographic groups at significantly higher risk other than senior citizens and indigenous Filipinos such as persons deprived of liberty, persons with disabilities, Filipinos living in high-density areas, students
B5Overseas FIlipino Workers
B6Other remaining workforce
CRest of the Filipino population not otherwise included in the above priority groups

Efficacy Rates of Pfizer-BioNTech Vaccine

According to the official website of Pfizer, the Pfizer-BioNTech vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA).

Your Reactions

Do you have clarifications/ comments about this article? Please feel free to drop one below.

0 comments… add one

Leave a Reply

Your email address will not be published. Required fields are marked *